With legal access to psilocybin therapy growing, researchers are committed to understanding and quantifying its potential benefits. As the founder of Complex Biotech Discovery Ventures (CBDV) — a British Columbia-based research laboratory that focuses on extraction optimization, analytical testing, and chemical process development for the cannabis and psilocybin industries — Dr. Markus Roggen holds a unique perspective on the issue.
In this written Q&A, Dr. Roggen discusses the importance of understanding psilocybin’s chemistry, getting licensed to research psilocybin by Health Canada, and the similarities and differences of cannabis vs. psilocybin research. The interview also covers psilocybin’s growing prevalence and popularity, the unknowns that researchers hope to understand, and more!